GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foamix Pharmaceuticals Ltd (NAS:FOMX) » Definitions » ROE %

Foamix Pharmaceuticals (Foamix Pharmaceuticals) ROE % : -425.52% (As of Dec. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Foamix Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Foamix Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2019 was $-151.28 Mil. Foamix Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2019 was $35.55 Mil. Therefore, Foamix Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2019 was -425.52%.

The historical rank and industry rank for Foamix Pharmaceuticals's ROE % or its related term are showing as below:

FOMX's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.1
* Ranked among companies with meaningful ROE % only.

Foamix Pharmaceuticals ROE % Historical Data

The historical data trend for Foamix Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foamix Pharmaceuticals ROE % Chart

Foamix Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROE %
Get a 7-Day Free Trial -22.09 -25.42 -66.18 -92.25 -173.43

Foamix Pharmaceuticals Quarterly Data
Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.10 -71.47 -109.80 -162.66 -425.52

Competitive Comparison of Foamix Pharmaceuticals's ROE %

For the Biotechnology subindustry, Foamix Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foamix Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foamix Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Foamix Pharmaceuticals's ROE % falls into.



Foamix Pharmaceuticals ROE % Calculation

Foamix Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2019 is calculated as

ROE %=Net Income (A: Dec. 2019 )/( (Total Stockholders Equity (A: Dec. 2018 )+Total Stockholders Equity (A: Dec. 2019 ))/ count )
=-95.178/( (92.182+17.575)/ 2 )
=-95.178/54.8785
=-173.43 %

Foamix Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2019 is calculated as

ROE %=Net Income (Q: Dec. 2019 )/( (Total Stockholders Equity (Q: Sep. 2019 )+Total Stockholders Equity (Q: Dec. 2019 ))/ count )
=-151.28/( (53.529+17.575)/ 2 )
=-151.28/35.552
=-425.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2019) net income data. ROE % is displayed in the 30-year financial page.


Foamix Pharmaceuticals  (NAS:FOMX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2019 )
=Net Income/Total Stockholders Equity
=-151.28/35.552
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-151.28 / 0.54)*(0.54 / 81.371)*(81.371 / 35.552)
=Net Margin %*Asset Turnover*Equity Multiplier
=-28014.81 %*0.0066*2.2888
=ROA %*Equity Multiplier
=-184.9 %*2.2888
=-425.52 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2019 )
=Net Income/Total Stockholders Equity
=-151.28/35.552
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-151.28 / -151.28) * (-151.28 / -149.724) * (-149.724 / 0.54) * (0.54 / 81.371) * (81.371 / 35.552)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0104 * -27726.67 % * 0.0066 * 2.2888
=-425.52 %

Note: The net income data used here is four times the quarterly (Dec. 2019) net income data. The Revenue data used here is four times the quarterly (Dec. 2019) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Foamix Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Foamix Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Foamix Pharmaceuticals (Foamix Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2 Holzman Street, Weizmann Science Park, Rehovot, ISR, 7670402
Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.
Executives
Ilan Hadar officer: CFO & Country Manager C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Stanley Hirsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Anna Kazanchyan director 933 MAMARONECK AVENUE, SUITE 103, MAMARONECK NY 10543
Anthony D Bruno director C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Stern director C/O THCG, INC, 650 MADISON AVENUE, 21ST FL, NEW YORK NY 10022
Rex Bright director 5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart officer: Chief Scientific Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski director, officer: CEO C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Mutya Harsch officer: CLO and General Counsel C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley officer: Chief Commercial Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Headlines

From GuruFocus